Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Nicole Birrer"'
Autor:
Oliver Van Oekelen, Nicole Birrer, William Wesson, Vincent L. Galate, Edward R. Scheffer Cliff, Aaron M. Goodman, Al-Ola Abdallah, Rajshekhar Chakraborty, Vinay Prasad, Ghulam Rehman Mohyuddin
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 11, Pp 1-4 (2022)
Externí odkaz:
https://doaj.org/article/61a6cc8b32914c95ae3ea1eab52fca80
Autor:
Elizabeth O'Donnell, Anuj Mahindra, Andrew J. Yee, Valentina Nardi, Nicole Birrer, Nora Horick, Darrell Borger, Dianne Finkelstein, John A. Iafrate, Noopur Raje
Publikováno v:
EBioMedicine, Vol 2, Iss 1, Pp 71-73 (2015)
Whole genome sequencing studies have identified several oncogenic mutations in multiple myeloma (MM). As MM progresses, it evolves genetically underscoring the need to have tools for rapid detection of targetable mutations to optimize individualized
Externí odkaz:
https://doaj.org/article/bdf185abc26248c4a590ac86137b55f1
Autor:
Oliver Van Oekelen, Nicole Birrer, William Wesson, Vince Galate, Aaron Goodman, Al-Ola Abdallah, Rajshekhar Chakraborty, Vinay Prasad, Ghulam Rehman Mohyuddin
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S64-S65
Autor:
Catherine Wheeler, David Tamang, Jeffrey G. Supko, Edward N. Libby, Andrew Yee, Jesus G. Berdeja, Noopur Raje, Robert J Markelewicz, Peter M. Voorhees, Simon S. Jones, Min Yang, Jill N. Burke, Ellen E. Wallace, William I. Bensinger, Nicole Birrer, Paul G. Richardson
Publikováno v:
The Lancet Oncology. 17:1569-1578
Summary Background Histone deacetylase (HDAC) inhibitors are an important new class of therapeutics for treating multiple myeloma. Ricolinostat (ACY-1215) is the first oral selective HDAC6 inhibitor with reduced class I HDAC activity to be studied cl
Autor:
Matthew J. Cotton, Nicole Birrer, Matthew Meyerson, Daniel Gray, Birgit Knoechel, Yotam Drier, Guangwu Guo, Bang Wong, Noopur Raje, Jesse S. Boehm, Sora Kim, Todd R. Golub, Andrew Yee, Jens G. Lohr, Joshua Gould, Cheng-Zhong Zhang, Gavin Ha
Multiple myeloma (MM) remains an incurable disease, with a treatment-refractory state eventually developing in all patients. Constant clonal evolution and genetic heterogeneity of MM are a likely explanation for the emergence of drug-resistant diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c9f07c689d03c0d2aee7fc0f9cf743b
https://europepmc.org/articles/PMC5426804/
https://europepmc.org/articles/PMC5426804/
Publikováno v:
American journal of clinical oncology. 41(3)
Women with a BRCA1 or BRCA2 mutation are recommended to undergo prophylactic (or risk reducing) bilateral salpingo-oophorectomy (BSO) before age 40, resulting in surgical menopause. Given the concerns of estrogen deprivation on overall health, hormon
Autor:
Darrell R. Borger, John Iafrate, Nicole Birrer, Nora Horick, Anuj Mahindra, Noopur Raje, Elizabeth O'Donnell, Dianne M. Finkelstein, Valentina Nardi, Andrew Yee
Publikováno v:
EBioMedicine
EBioMedicine, Vol 2, Iss 1, Pp 71-73 (2015)
EBioMedicine, Vol 2, Iss 1, Pp 71-73 (2015)
Whole genome sequencing studies have identified several oncogenic mutations in multiple myeloma (MM). As MM progresses, it evolves genetically underscoring the need to have tools for rapid detection of targetable mutations to optimize individualized
Autor:
Nicole Birrer, Elizabeth DiTavi, Rachel M. Clark, J. Alejandro Rauh-Hain, Marcela G. del Carmen, Olivia W. Foley
Publikováno v:
Journal of community health. 40(6)
To evaluate the effect of an educational intervention on four domains of health care utilization and cervical cancer prevention and screening in a Hispanic population. Data collected from a survey were used to design education strategies focused on f
It is more than 30 years since the seminal observations by Folkman of the development of new blood vessels (angiogenesis) in tumors. Ovarian cancer remains the most lethal gynecologic malignancy in the US, and angiogenesis is a particularly important
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a63574ceeb38b9a70781b72c882cfe2
https://doi.org/10.1016/b978-0-12-803963-2.50006-5
https://doi.org/10.1016/b978-0-12-803963-2.50006-5
Autor:
Daniel C. Gray, Yotam Drier, Bang Wong, Birgit Knoechel, Gavin Ha, Cheng-Zhong Zhang, Guangwu Guo, Sora Kim, Andrew Yee, Jens G. Lohr, Noopur Raje, Jesse S. Boehm, Nicole Birrer, Joshua Gould, Matthew Meyerson, Todd R. Golub
Publikováno v:
Blood. 128:800-800
Continuous genomic evolution has been a major limitation to curative treatment of multiple myeloma (MM). Frequent monitoring of the genetic heterogeneity in MM from blood, rather than serial bone marrow (BM) biopsies, would therefore be desirable. We